A new degrader strategy has been previously proposed to mitigate platelet toxicity associated with Bcl-xL degraders. This strategy consists of selectively degrading Bcl-xL by the von Hippel-Lindau ...
HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease. Sean Korbitz had his first bout with cancer — a brain tumor discovered after six ...
The Von-Hippel Lindau (VHL) gene encodes for a tumor suppressor protein, pVHL, which is responsible for the regulation of a family cancer syndrome. Mutations in pVHL render the protein non-functional ...
CURE spoke with Stacy Lloyd, board member of the VHL Alliance, to better understand VHL and its impact on cancer. Kristie L. Kahl: Can you just explain what VHL is? Stacy Lloyd: VHL is short for von ...
Moderate to advanced chronic kidney disease is an underappreciated burden of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC) treated with surgery, which also includes frequent disease ...
Belzutifan makes von Hippel-Lindau disease more manageable, according to an expert. Approval of belzutifan for treatment of kidney cancers and other neoplasms associated with von Hippel-Lindau (VHL) ...
Anti-proliferative effects of sorafenib in clear cell renal cell carcinoma (CCRCC) cell lines: Relationship to von Hippel Lindau protein (pVHL) expression and hypoxia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback